Having trouble accessing articles? Reset your cache.

Gevokizumab: Phase I/II started

Xoma said NIH's National Eye Institute began an open-label, U.S. Phase I/II trial to evaluate 60 mg gevokizumab every 4

Read the full 209 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE